ArticleScientific reports2025
A redox-dependent switch governing sensory axon degeneration and regeneration.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Zebrafish (Danio rerio) fin amputation is a widely used model for studying sensory axon degeneration and regeneration. After injury, sensory neuron terminals rapidly degenerate before regenerating. While reactive oxygen species (ROS), particularly hydrogen peroxide (H₂O₂), are known to promote axon regeneration through epidermal mechanisms, their role in degeneration remains unclear. Here, we identify mitochondrial superoxide and reactive nitrogen species (RNS), specifically peroxynitrite, as key drivers of axon fragmentation. Using AlphaFold and DeepNitro predictive modeling, we identified conserved nitration and nitrosylation sites in NMNAT rather than SARM1, two key drivers of a known axon destruction pathway, suggesting the possibility of a redox-dependent regulatory mechanism. We further explored the role of NADPH in axon degeneration since cyba mutants that do not utilize NADPH to generate ROS display delayed sensory axon degeneration. Pharmacological NADPH treatment significantly reduced amputation-induced sensory axon degeneration while enhancing regeneration. NADPH co-administration also mitigated paclitaxel-induced axon loss and improved the tactile response in a model of chemotherapy-induced peripheral neuropathy. These findings reveal a complex interplay between ROS and RNS in axon degeneration and regeneration, positioning NADPH as a promising therapeutic candidate for oxidative stress-related neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.